Droxidopa

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

屈昔多巴是一种精神活性化合物，是神经递质去甲肾上腺素（去甲肾上腺素）和肾上腺素（肾上腺素）的前药。

Droxidopa is a psychoactive drug and acts as a prodrug to the neurotransmitters norepinephrine (noradrenaline) and epinephrine (adrenaline).

——

Droxidopa (200 mg/kg;i.p.) alters dopamine neuron and prefrontal cortex activity and improves attention-deficit/hyperactivity disorder-like behaviors in rats.Droxidopa (10, 20 mg/kg; i.p.) significantly increases the paw withdrawal latency and inhibits mechanical hypersensitivity to thermal stimulation in 6-OHDA-lesioned rats at the 5th week after surgery. Animal Model:250-380g male Sprague-Dawley rats Dosage:200 mg/kg (10 mg/kg, i.p. benserazide was given to the animals at 20 or 30 min prior to L-DOPS injection) Administration:I.p.Result:Significantly decreased hyperactivity of BZ-pretreated SHR/NCrl at 30 (P < 0.01) and 40 min (P < 0.05) post-injection, improved inattention-like behavior of SHR/NCrl, and ameliorated impulsive-like behavior of SHR/NCrl and Wistar rats.

L-DOPS | SM 5688

Endocrinology/Hormones

Adrenergic Receptor

Adrenergic Receptor

Neurological Disease

——

23651-95-8

213.19

C9H11NO5

>98% (HPLC)

Ethanol: <1 mg/mL (<1 mM); Water: <1 mg/mL (<1 mM); DMSO: <1 mg/mL (<1 mM)

O=C(O)[C@H](N)[C@H](C1=CC=C(O)C(O)=C1)O

(2R,3S)-2-Amino-3-(3,4-dihydroxyphenyl)-3-hydroxypropanoic acid

(-20℃)

With Ice Pack

≥ 2 years